FARAZ TYEB: Open Payments
NPI 1639458417 · EPHRATA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$819 in 48 payments from 7 companies in 2025. Trend: 2023 $721 · 2024 $954 · 2025 $819
Food & beverage: $819
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 14 | $275 |
| ABBVIE INC. | 13 | $161 |
| Axsome Therapeutics, Inc. | 8 | $143 |
| Neurocrine BioSciences, Inc. | 7 | $126 |
| Alkermes, Inc. | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
Products named: Qelbree, VRAYLAR, Auvelity, INGREZZA, LYBALVI, ABILIFY ASIMTUFII, INVEGA SUSTENNA.
Industry payments across PA — which companies pay providers there.
